newsinsights

Browse our recent blogs, articles and papers below and sign up here for our regular newsletter. 

A Budding Opportunity for European Investors: The Investment Case for Medical Cannabis | CBDX

Introduction

Cannabis has been cultivated as a medicinal herb for more than 5,000 years. The earliest signs of its use as an herbal remedy appeared sometime around 2,500 BCE (1). The plant has also been used as a vehicle for spiritual enlightenment and for recreation. But only recently has it come out of the shadows and into the mainstream as a potentially powerful tool in modern medicine.

For most of modern history, the use of cannabis was widely prohibited throughout the western world. Within the last few decades, and especially in more recent years, use of cannabis and views surrounding the plant have become more liberalised, fuelling growth a legal industry. Several countries, including Germany,Italy and Denmark, have legalised cannabis for medical use (2). Many more are in the process of legalising cannabis for medical usage.

The growing number of jurisdictions with legal medical cannabis use has led to the creation of a legitimate, multi-faceted industry. The legal cannabis space includes not only growers and producers, but also service-oriented support companies, which provide specialised equipment and technology.

The Growing Opportunity

This growing industry naturally presents an opportunity for investors, equivalent or larger than investing in alcohol producers in the post-prohibition period.Many companies involved in the legal industry have issued shares for public trading on open exchanges. The number of public companies is now prolific enough to support a broad basket of cannabis-related securities. Following the broad legalisation of cannabis in Canada in 2018, the investable universe expanded rapidly, leading to the creation of exchange-traded funds focusing on the legal industry.

The 2019 sell-off in cannabis stocks has corrected lofty expectations to the extent where the stocks themselves were oversold and are once again showing value against their long-term growth and valuation targets. With numerous medical studies now in place and regulatory easing within sight, there are multiple positive catalysts to push the industry forward. 

But while North American investors are well serviced by ETFs targeting the legal cannabis sector, European investors are not……yet.

We believe there is a large opportunity to bring the first medical cannabis focused ETF in Europe, structured to meet current laws with the ability to evolve as the regulatory environment changes. HANetf has partnered with Purpose Investments, the leading manager in the space, to create The Medical Cannabis and Wellness UCITS ETF (CBDX), Europe’s first medical cannabis and wellness fund. The ETF provides a convenient and easy access to the legal cannabis industry for European institutional and retail investors.

The fund is comprised of constituents with significant business activities in the medical cannabis, hemp and CBD industries, such as producers and suppliers of legal medical cannabis, biotechnology companies that are engaged in research and development of cannabinoids and other legal tertiary companies.

Cannabis is on Everyone's Lips: Get to Know the Terminology

Cannabinoids

The class of chemical compounds that includes the primary components found in marijuana. Cannabinoids act on receptors in the brain, altering the release of neurotransmitters to produce psychoactive and therapeutic effects.

THC (Tetrahydrocannabinol)

The primary psychoactive chemical compound in marijuana, responsible for producing a euphoric high.

CBD (Cannabidiol)

The primary non-psychoactive chemical compound in marijuana, believed to be responsible for alleviating anxiety and producing other therapeutic eects.According to a report from the World Health Organization, “In humans, CBD exhibits no eects indicative of any abuse or dependence potential. To date, thereis no evidence of public health related problems associated with the use of pure CBD.” (3)

Edibles

Any food or beverage that contains THC, CBD or a combination of both. Due to the way the body metabolises the chemicals in the stomach, the effects appear more slowly and can last much longer than they would if inhaled, which can produce more targeted therapeutic uses and outcomes.

Concentrates

A wide variety of products that contain extracted and concentrated versions of cannabinoids. This includes oils, waxes and other forms of the extracted chemicals which may be used to create edibles or other types of infusions for consumption.

Defining the Cannabis Market 

Flower, edibles, waxes, oils - there are several dimensions to the products offered in the cannabis industry as a whole, which can be narrowed down into three key genres.

1) Medical & Wellness: Products that focus on the well being of patients and consumers using cannabis for medicinal purposes. This included both products derived from cannabis, as well as hemp (CBD).

2) Recreational: Products that are intended for recreational uses, similar to how alcohol is consumed globally. Typical forms include but are not limited to flower or “bud”, extracts such as oils and waxes, beverages, as well as various synthetics.

3) Ancillary Services: Include products and services that support the production of the final product such as a bottling, machinery and fertilisers.

Under these three genres, the investable cannabis market can be broken down into 4 main segments:

1) Canadian Operators

With recreational Cannabis consumption federally legal, most operators in this market are vertically integrated, and a variation of the below business lines, with few operating exclusively in one segment of the value chain. These operations typical dispute under both a medical and recreational license, selling all types of products to its consumer base.

  • Cultivation: Cannabis cultivation is a term that refers to growing cannabis in a commercial facility. Cultivation can occur outdoors, but it is much more likely to be indoors in a hydroponic (soilless) set-up. These are colloquially known as “growers”.
  • Extraction: Extraction refers to the process of extracting or concentrating the most potent compounds from the plants, essentially removing the oil found in the trichomes “crystals” from the bud of the plant. The resulting products from the extraction process (the concentrates or extracts) are therefore a highly concentrated and potent form of THC and other cannabinoids. The extracted concentrates can be in the form of oils, pills, and other forms, and can also be used to make edibles like baked goods, candies, and infused beverages.
  • Retail Distribution: Retail distribution refers to the process of selling the cannabis directly to consumers, only in relation to the recreational market

 

2) US Multi-State-Operators (M.S.O) 

In the United States market, recreational cannabis is yet to be legalised at a federal level, however over 11 states and counting have bucked the trend and made it legal at a state level. Multi-state-operators (M.S.O) are companies which operate only in state legal jurisdictions in the medical and recreational cannabis market. At a federal level these companies are still considered to be operating illegally. Similar to a Canadian operator, they are integrated verticals, operating in the entire value chain.

3) US Hemp/CBD

Although recreational cannabis has not been federally legalised, under the 2018 Farm Bill, hemp has now because federally legal. Hemp (a cannabis plant that contains a very low amount of THC) has enabled the legal creation of extracts in the form of CBD, drumming up the business incentive for swaths of companies to enter the space.

US CBD Usage Trend: 2014-2022 (4) 

 

4) International Medical Companies

Outside of North America, the cannabis market continues to bud. With only two countries globally which have federally legalized recreational cannabis (Canada and Uruguay) the investable market outside of this are typically medical-only companies, and ancillary services. These companies are predominantly located in Australia, Israel, South America (such as Colombia) and the United Kingdom. In fact, the largest producer and exporter of medical-grade cannabis in the world is the United Kingdom, growing close to 100 metric tonnes a year. (5)

The Medical Market Remains a Frontier for Growth

With the global medical cannabis market estimated to be worth north of $150B (CAD) (6) over the next 10- 15 years, the Canadian experience in both the medical and recreational markets oers a proof-of-concept model for smart and sensible cannabis regulation that can be replicated and implemented in new markets moving forward.

 

Use of Cannabis for Medical Purposes

Scientific understanding of the uses of cannabis for medical purposes is still in its infancy. For most of modern history, scientists had been restricted in their ability to research cannabis and its constituent ingredients. However, with the growing wave of liberalisation, researchers are increasingly able to investigate and unlock the secrets of the plant.

Researchers delving into the medical uses of cannabis typically focus on CBD. While definitive results are still elusive at this point, preliminary and mid-stage research suggests that cannabis, and particularly CBD, has the potential to reduce anxiety, reduce inflammation and relieve pain and control nausea related to other treatments, such as chemotherapy. Additionally, it has been shown to relax tight muscles in patients with multiple sclerosis and stimulate appetite for those suffering from cancer and AIDS.

Medical cannabis is also used to treat a number of other conditions, although with less understanding of its benefits. These conditions include Alzheimer’s disease, Crohn’s disease, eating disorders, epilepsy, glaucoma, muscular disorders and mental health condition, such as post-traumatic stress disorder.Research into these areas is considered promising, although early.

One of the difficulties of understanding the efficacy of medical cannabis is the wide variety of ways to administer it. Medical cannabis can be consumed in multiple ways, including the most traditional method, smoking. It can also be inhaled through a device known as a vaporiser, which produces a vapor that does not contain combusted material from burning. Edibles, lotions and indigestible oils are also methods of delivery, each with its own time frames for onset and duration, in addition to differing effects.

 

A Budding Opportunity for European Investors

With Canada and the U.S. stealing the majority of the limelight in cannabis news, countries outside of North America often push the envelope in the shadows. Europe particularly has seen meaningful advances in both decriminalization and medical legalisation of cannabis.

As of January 2019, Europe has 28 countries with medical cannabis legalized in some form, and 20 of those have decriminalized the possession or personal consumption of small quantities.

The growth of the global medical cannabis market has particular importance for European businesses as countries like UK, Italy, Netherlands and Switzerland are regional leaders in the production and export of medical grade cannabis. In fact, the UK is the world’s largest single producer and exporter of medical grade cannabis, producing close to 100 tonnes a year. (8)

 

Untapped Growth Potential

While cannabis has been around for thousands of years, modern science is just beginning to scratch the surface of what is possible from a medical standpoint. A number of medical uses have already been discovered and studied extensively, with promise shown particularly for cancer, AIDS and multiple sclerosis patients. As views and laws surrounding cannabis continue to liberalize around the world, more scientific inquiry will follow.

THC and CBD are the two common chemical components when discussing cannabis. However, researchers have isolated 113 different cannabinoids, providing scientists with ample grounds for further exploration.

The landscape is not only ripe for further scientific discovery, but also for investors. Cannabis has, in essence, become a new sort of commodity. An entirely new industry and market has developed relatively quickly in the last decade from a plant that humans have been using for thousands of years. Financial backers no longer shy away from supporting legal cannabis companies. Cannabis is becoming mainstream and, in our view, has great potential to deliver long-lasting social, medical, industrial and economic effects.

Most Researched Cannabinoids: Effects and Applications

 

Investing in the Green Gold Rush: The Medical Cannabis and Wellness UCITS ETF (CBDX)

In January 2020, HANetf and Purpose Investments launched the The Medical Cannabis and Wellness UCITS ETF (CBDX), an UCITS compliant ETF domiciled in Ireland. The fund provides physical replication of the Medical Cannabis and Wellness Equity Index, a rules-based benchmark capturing companies involved in the legal medical cannabis, hemp and CBD industry.

Advantages: 

  • Distinctive: As the first product of its kind in Europe, CBDX provides investors with access to a unique new sector
  • Transparent, modern approach: CBDX follows a rules-based free float weighted index ensuring only investible companies are included in the ETF
  • Diversified: In a single trade, CBDX provides exposure to a basket of companies from US and Canada with high exposure to the medical cannabis theme
  • Governance: CBDX embeds multiple levels of governance and contains constituents engaged in legal, licensed and regulated activities
  • Accessible: Listed on major European exchanges and available on wide variety of execution and broker platforms
  • Legal analysis: During the construction of this ETF, there has been significantly more legal analysis across multiple jurisdictions than would occur during the typical ETF product development process. Providing reassurance for investors that the fund is in compliance with all relevant local laws and listing standards.

 

Key Risks:

  • The value of equities and equity-related securities can be affected by daily stock and currency market movements
  • Investors' capital is fully at risk and investors may not get back the amount originally invested
  • Exchange rate fluctuations could have a negative or positive effect on returns

 

CBDX Features:

- The ETF comprises securities with significant business activities in the medical cannabis, hemp and CBD industries

  • Producers and suppliers of medical cannabis
  • Biotech companies involved in the research and development of cannabinoids
  • Hydroponics and equipment suppliers
  • Companies leasing property to medical cannabis producers
  • Companies with an investment focus on the medical cannabis sector
  • Companies providing software solutions to the medical cannabis industry
  • Providers of medical cannabis consumer products 

 

- Full physical replication 

- Constituents are capped at 10% during quarterly rebalances to ensure diversification 

- Multiple currency lines - GBP, USD and EUR

 

Download the full whitepaper 'A Budding Opportunity for European Investors: The Investment Case for Medical Cannabis' 

Tell us how we can help

Select Investor Type Please Choose one of the Following options to enter the site:

Individual Investor
Institutional Investor

Welcome to HANetf

To start your visit, you have read and accepted our terms and conditions:

HANetf Limited (“HANetf”), is an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority (“FCA”).

Our corporate website www.hanetf.com (referred to as the “Site”) is owned by HANetf. By accessing and using the Site you agree to be bound by all terms and conditions which are set out on the Site from time to time, which govern such access and use (the "Terms and Conditions").

Our company number is 10697042. Our registered address is City Tower,  40 Basinghall St, London EC2V 5DE.

This website is for information only. It does not provide investment, tax or legal advice or recommendations.

Use of this Website shall be governed by and construed in accordance with English law and any dispute arising in relation to this Website is subject to the jurisdiction of the English courts.

Distribution of Information:

The distribution of the information and material on this website may be restricted by law in certain countries. None of the information is directed at, or is intended for distribution to, or use by, any person or entity in any jurisdiction (by virtue of nationality, place of residence, domicile or registered office) where publication, distribution or use of such information would be contrary to local law or regulation, or would subject HANetf or any funds it markets to any registration or licensing requirements in such jurisdiction.

You must inform yourself about, and observe any such restrictions in your jurisdiction and by accessing this website you represent that you have done so. The information on this website is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States to or for the benefit of any United States person (being residents of the United States or partnerships or corporations organised under the laws thereof). The funds on this Website have not been registered in the United States under the Investment Company Act of 1940 and interests therein are not registered in the United States under the Securities Act of 1933.

Liability & Indemnity:

HANetf is not responsible for the accuracy, completeness or reliability of any data, statistics, commentary or content in any media format on www.hanetf.com. HANetf will not be held responsible for any financial losses incurred as a result of believing the content of materials on this website; or materials and content linked to from this website. Investors should read the Prospectus and KIID and take independent legal, tax and investment advice before investing in any fund.

If you do not comply with the terms and conditions of this website, you may not hold HANetf responsible for any liabilities, losses or damages derived from use of this website.

Risk Warnings:

Never forget that:

  • * The value of securities and funds and the income from them may go up and down and are not guaranteed
  • * You may not get back the amount you invested
  • * Don’t invest in anything based on past performance
  • * Exchange rate changes may impact investment performance
  • * Political actions may impact investment performance
  • * Changes in credit rating may impact investment performance
  • * Changes in tax policies may impact investment performance
  • * Applications to invest should be made on the basis of the relevant prospectus
  • * No materials available on www.hanetf.com constitute investment advice

Specific risk warnings are set out in the prospectus and the supplement for the relevant sub-fund: http://www.hanetf.com/funds/

Website user categorisation

ONLY APPLICABLE IF YOU ARE AN INSTITUTIONAL INVESTOR

The professional investor section of the website and its content is restricted to “Professional Investors” only (as defined below) and is not intended for retail or private investors.

By entering this website, you agree that you are an “Institutional Investor” as defined here: https://www.handbook.fca.org.uk/handbook/COBS/3/5.htmland have read, understood and accepted the conditions.

In accessing the website as a Professional Investor you will be undertaking, warranting and representing to HANetf that you are a Professional Investor. Please note that HANetf will be acting in reliance upon your undertaking, warranty and representation and you shall indemnify us and hold us harmless against all claims liabilities, losses, damages, costs and expenses incurred or suffered by us by reason of any breach of such undertaking, warranty and representation.

As a matter of general policy HANetf will not conduct regulated investment activities with any person as a result of their receiving information from the website, unless agreed otherwise with a professional investor.

Disclaimer:

* Past performance is meaningless and should not be used to judge future performance of any security or fund. Opinions, commentary and estimates reflect a judgement at the date of publication and may not be accurate at the date of reading. Publication of content on www.hanetf.com does not mean the content piece reflects the opinions of HANetf, or its employees, directors or shareholders. HANetf opinions and estimates can change at any time, without notice.

* HANetf does not guarantee the accuracy, consistency, availability, believability or completeness of any data or materials on this website. HANetf may change any data or materials at any time, for any reason without notice.

* The price, value, yield and liquidity of any security or fund can go up and down and may be impacted by Currency Risks, Liquidity Risks, Political Risks, Credit Risks, Tax Risks and Market Risks. Professional advice should be taken before investing in any security or fund.

* HANetf does not guarantee the security of this website. You use this website at your own risk.

* HANetf may change the terms of use for www.hanetf.com at any time, for any reason, without notice.

Cookie Policy:

HANetf will use Cookies to collect data about your computer including browser type, IP address and operating system. HANetf will also monitor your use of www.hanetf.com , including what links you have clicked, what files you download and your behaviour on website pages. We do this to improve our services and serve you materials we believe are relevant to you, and to comply with local regulations. By clicking through, you agree to HANetf using cookies as described here. Please note that you can change your browser settings to delete cookies, but this may impact your experience on www.hanetf.com

Intellectual Property: All content on www.hanetf.com is the intellectual property of HANetf is subject to copyright with all rights reserved and may not be copied, shared, sold, licensed, posted, reproduced or changed without permission of HANetf.

HANetf has the right to change anything on this website without notice or reason.

This website contains numerous registered and unregistered trademarks belonging to the HANetf or our partners. If you are in doubt as to whether an item is a trademark of the HANetf or our partners, please contact us for clarification at the registered office.

Unless otherwise specified, this website and its content are owned by the HANetf, and may contain information, text, graphics, video, software, logos, and other materials ("Content") that are protected by copyright, trademarks, or other proprietary rights. No permission is granted to upload, copy, modify, post, frame, amend or distribute Content in any way without obtaining the prior written permission of HANetf. All intellectual property rights in any part of the world which subsist in the contents of this Website and which belong to HANetf save as expressly granted, hereby reserved Any third party licensor trademarks referenced herein are trademarks of such third party licensor and have been licensed for use by HANetf. The securities incorporating third party indexes are not created, sponsored, endorsed, recommended or promoted by such third party licensors and the licensors shall have any no liability in connection with the securities.

Linked Websites: HANetf may provide links to external websites on www.hanetf.com or in newsletters, publications, content or email communications.

Content on external websites is not controlled by HANetf and users access external Websites at their own risk. A link to a website does not mean HANetf believes, endorses or supports any opinions or information contained on that website.

Monitoring:

Your use of this website may be monitored by HANetf or its service providers, and the resultant information may be used by HANetf for its internal business purposes or in accordance with the rules of any applicable regulatory or self-regulatory organisation.

Governing Law & Jurisdiction:

This legal notice and all issues regarding our Site are governed by English law and are exclusively subject to the English courts.

1.Confidentiality

We will keep your information confidential and only use it within our group (which means our affiliated companies, successors and assigns), and only transfer it to third parties in the manner described in the below section labelled “Use of third parties”, unless we are under a duty to disclose or share your personal data in order to comply with a court order or other legal or regulatory requirement.

2.Personal Data

HANetf will use your personal data only for the purposes and in the manner set forth in this Privacy Policy which describes the steps taken to ensure our processing of your personal data is in compliance with the General Data Protection Regulation ((EU) 2016/679) ("GDPR") and any implementing legislation ("Data Protection Legislation").

How and why we collect personal data

HANetf will use your personal data only for the purposes and in the manner set forth in this Privacy Policy which describes the steps taken to ensure our processing of your personal data is in compliance with the General Data Protection Regulation ((EU) 2016/679) ("GDPR") and any implementing legislation ("Data Protection Legislation").

We will keep your information confidential and only use it within our group (which means our affiliated companies, successors and assigns), unless we are forced to share your personal data to comply with a court order or other legal or regulatory requirement.

The personal information we may collect might include your name, address, email address, company details and any other relevant information that may be included within correspondence. In addition, details of your visits to our website including (but not limited to) IP address, cookies, traffic data, location data, weblogs and other information related to what pages are accessed and when may be collected. Also, for legal reasons, in order to access our website, details of your investor type, and location will be collected, with such collection being carried out in compliance with the Privacy and Electronic Communications Regulations (“PECR”). This data would be collected to customise our users’ visits to our website.

If you are accessing sections of our website that are password protected or have entered the website through a link in an email, our website will identify you as an individual and may collect data including information about the pages you visit, the documents you download or other information to enhance and personalise your future interaction with our website.

Any information collected about you may be associated with other identifying information we hold.

HANetf will retain and process your personal data only when this is necessary to achieve our commercial or business objectives and to comply with our regulatory obligations. After careful consideration, HANetf has concluded the processing of personal data for the reasons mentioned shall be considered necessary, as there would not be another way of achieving the identified interest of the firm.

All information you provide to us is stored on secure servers. Information may be transferred, stored and processed by third parties. It may also be processed by staff operating outside the European Union (“EU”) who work for us or for one of our suppliers of services, such as data processors or providers of back up services. You should be aware that in territories outside the European Economic Area (“EEA”), laws and practices relating to the protection of personal data are likely to be different and, in some cases, may be weaker than those within the EEA. By submitting your personal data, you are agreeing to this transfer, storing or processing.

Such transfers outside the EU will only take place where either (i) the Commission has decided that such third country ensures an adequate level of protection; or (ii) we have provided appropriate safeguards, and on the condition that enforceable rights and effective legal remedies are available for you. If you use our services while you are outside the EU, your information may be transferred outside the EU in order to provide you with those services. By submitting your personal data, you agree to the potential transfer, storing and other processing described above. We will take all steps reasonably necessary to ensure that your personal data are treated securely and in accordance with this Privacy Policy.

3.Use of third parties

Communicating via the internet and sending information to you by other means necessarily involves your personal information passing through or being handled by third parties, but we do not sell or distribute without your permission your personal information to third parties for purposes of allowing them to market products and services to you.

We have also reviewed all key third party agreements where EU personal data is being processed to ensure they are GDPR compliant and that your rights described herein are being protected.

4.What safeguards we have in place

HANetf has security measures in place to protect the loss, misuse and alteration of the information under our control. As no data transmission over the internet can be guaranteed as 100% secure, we cannot ensure or warrant the security of any information you transmit to us and you transfer the data at your own risk. We endeavour to use appropriate security measures, including systems security, backups, business recovery and breach notification procedures, monitoring and testing procedures.

Although we will do our best to protect your personal data, we cannot guarantee the security of your personal data transmitted to our Site and accordingly any transmission is at your own risk. However, once we have received your information, we will use all appropriate procedures and security measures to try to prevent unauthorised access to or disclosure of your personal data.

5.What rights you have with regards to your personal data we process

You have the right to access your personal data and request a copy of the information held by us about you. You also have the right to ask for your information to be transferred to another organisation or to yourself. Where such requests are manifestly unfounded or excessive, we will inform you and we may charge a reasonable fee or refuse to respond to such a request.

You have the right to ask us not to process your personal data for marketing purposes. We will inform you if we intend to use your personal data for such purposes. You can exercise your right to prevent such processing by contacting us directly. You can also exercise the right and change your marketing preferences or restrict any specific uses of your personal data at any time by contacting us.

The accuracy of your information is important to us. We review the information we hold to ensure it is up to date and accurate. You have the right to correct any inaccuracies in the details we hold about you – if you change your email address or notice any other information we hold is inaccurate or out of date, please contact us. You have the right to obtain without undue delay the rectification of any inaccurate personal data concerning you.Your rights to access, rectify, erase or restrict your personal data stated above will be processed by HANetf usually within 30 days of receiving your request. However, HANetf may notify you within such timeframe of an increased time period to process your request and its reason. Where HANetf believes the request is unreasonable it shall notify you and refuse to process your request.

6.Complaints

If you have any questions regarding this Privacy Policy and our privacy practices you can contact us via email at [email protected] or in writing to Compliance, HANetf, City Tower, 40 Basinghall St, London EC2V 5DE.

7.Contact information

If you believe your personal data has been processed by HANetf in a way that does not comply with GDPR, you have the right to lodge a complaint with us directly [email protected] or with a supervisory authority.

If you believe HANetf did not take action on a request you have sent; or informed you without delay and at the latest within one month of receipt of the request of the reasons for not taking action and on the possibility of lodging a complaint with a supervisory authority and seeking a judicial remedy, you have the right to lodge a complaint with a supervisory authority.